Is Hims & Hers Health, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from very expensive to expensive, indicating a shift in perception regarding its valuation. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 74, a Price to Book Value of 22.96, and an EV to EBITDA of 89.10. In comparison, Guardant Health, Inc. has a P/E of -17.69, while Addus HomeCare Corp. shows a more reasonable P/E of 22.05, highlighting the relative expense of Hims & Hers.
Despite a strong year-to-date return of 105.87% compared to the S&P 500's 13.30%, the high valuation ratios suggest that the stock may not sustain such performance in the long run. The company's PEG ratio of 0.01 further emphasizes its high valuation relative to growth expectations, reinforcing the conclusion that it is overvalued in the current market context.